Paradigm Capital Management Inc. NY Reduces Holdings in Nature's Sunshine Products, Inc. $NATR

Key Points

• Paradigm Capital Management Inc. NY decreased its stake in Nature's Sunshine Products by 6.2%, selling 51,000 shares and leaving them with 768,200 shares valued at approximately $9.64 million.
• Several institutional investors have significantly increased their stakes, with GAMMA Investing LLC lifting its ownership by 2,090.2% during the same period.
• Wall Street analysts maintain a consensus Buy rating for Nature's Sunshine Products, with price targets averaging around $19.67, following their quarterly earnings report that exceeded expectations.

Paradigm Capital Management Inc. NY cut its position in shares of Nature's Sunshine Products, Inc. (NASDAQ:NATR - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 768,200 shares of the company's stock after selling 51,000 shares during the quarter. Paradigm Capital Management Inc. NY owned approximately 4.19% of Nature's Sunshine Products worth $9,641,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NATR. Millennium Management LLC bought a new stake in Nature's Sunshine Products in the fourth quarter worth about $1,135,000. Nuveen LLC bought a new stake in Nature's Sunshine Products in the first quarter worth about $437,000. Dimensional Fund Advisors LP raised its position in Nature's Sunshine Products by 3.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 856,701 shares of the company's stock worth $12,560,000 after acquiring an additional 30,464 shares during the period. Janney Montgomery Scott LLC bought a new stake in Nature's Sunshine Products in the first quarter worth about $340,000. Finally, Mackenzie Financial Corp bought a new stake in Nature's Sunshine Products in the first quarter worth about $287,000. 79.40% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NATR. Canaccord Genuity Group boosted their price target on shares of Nature's Sunshine Products from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, August 1st. DA Davidson reissued a "buy" rating and issued a $19.00 price target on shares of Nature's Sunshine Products in a research report on Tuesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $19.67.

Nature's Sunshine Products Price Performance

NATR stock traded up $0.42 during midday trading on Wednesday, reaching $17.22. The company had a trading volume of 120,013 shares, compared to its average volume of 112,515. Nature's Sunshine Products, Inc. has a 1 year low of $11.01 and a 1 year high of $18.06. The company has a market capitalization of $303.76 million, a P/E ratio of 23.27 and a beta of 1.11. The firm has a 50-day moving average price of $15.67 and a 200-day moving average price of $14.24.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.19. Nature's Sunshine Products had a net margin of 3.06% and a return on equity of 10.19%. The company had revenue of $114.75 million during the quarter, compared to analysts' expectations of $113.10 million. Nature's Sunshine Products has set its FY 2025 guidance at EPS.

Insider Buying and Selling at Nature's Sunshine Products

In related news, major shareholder Fosun Pharmaceutical Shanghai sold 2,854,607 shares of the stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $11.46, for a total value of $32,713,796.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Jonathan David Lanoy sold 5,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $16.51, for a total transaction of $82,550.00. Following the completion of the transaction, the chief accounting officer owned 50,051 shares of the company's stock, valued at approximately $826,342.01. The trade was a 9.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,869,603 shares of company stock valued at $32,961,680 in the last quarter. Company insiders own 5.60% of the company's stock.

Nature's Sunshine Products Profile

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.